Denise Visco, MD
Ophthalmology · York, PANPI 1790772937
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $150,758 of the $212,280 with a category attached, or 71.0%. 26 manufacturers reported payments, led by Lensar, Inc. at 36.8% of the total. Reporting peaked in 2019 at $108,975 and has fallen 74.7% since, to $27,592 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $1153.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$78K
- Omeros Corporation$68K
- Carl Zeiss Meditec, Inc.$49K
- Rayner Intraocular Lenses Limited$4K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Bausch & Lomb Americas Inc.$3K
- plus $7K from 20 others
Across 16 payments — averaging $6340.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lensar, Inc.$69K
- Oyster Point Pharma, Inc.$32K
What the payments were for
- Consulting fees$150,75871%
- Speaking & faculty fees$40,52019%
- Travel & lodging$3950%
- Food & beverage$20,59010%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 32 | $78,090 |
| Omeros Corporation | 17 | $68,364 |
| Carl Zeiss Meditec, Inc. | 41 | $48,845 |
| Rayner Intraocular Lenses Limited | 4 | $4,493 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,763 |
| Bausch & Lomb Americas Inc. | 9 | $2,695 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $1,491 |
| Ivantis, Inc | 6 | $1,481 |
| Sun Pharmaceutical Industries Inc. | 6 | $932 |
| Eyepoint US, Inc. | 2 | $668 |
| Oyster Point Pharma, Inc. | 7 | $382 |
| AbbVie(2 entities) | 12 | $290 |
| Novartis | 6 | $259 |
| Carl Zeiss Meditec USA, Inc. | 3 | $250 |
| Alcon | 8 | $249 |
| Rxsight Inc | 3 | $229 |
| Sight Sciences, Inc. | 4 | $159 |
| Quidel Corporation | 5 | $143 |
| Ocular Therapeutix, Inc. | 2 | $124 |
| Dompe US, Inc. | 1 | $103 |
| Bausch Health US, LLC | 1 | $102 |
| Kala Pharmaceuticals, Inc. | 2 | $81 |
| Shire North American Group Inc | 1 | $24 |
| Glaukos Corporation | 1 | $23 |
| Medline Industries LP | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$77,910
- OMIDRIA$72,599
- VisuMax$35,324
- ARTEVO 800$13,500
- VERACITY SURGICAL$11,438
- FORUM$10,125
- CIRRUS HD-OCT$7,500
- CIRRUS photo$7,500
- AT LISA$7,500
- IOLMaster 700$6,919
- CALLISTO eye$6,750
- Cataract Suite$5,625
- CT Lucia$4,500
- Tecnis IOL$3,750
- QUATERA 700$3,332
- CLARUS 500$2,625
- MIEBO$2,425
- Clarus 700$2,355
- OPMI Lumera 700$2,250
- RESCAN 700$2,250
How this compares
$212,280 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 26 | $21,952 |
| RestasisCyclosporine | 16 | $15,889 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,624 |
| Loteprednol Etabonate | 38 | $6,186 |
| Prednisolone Acetate | 189 | $4,574 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,174 |
| Brimonidine Tartrate | 16 | $1,479 |
| Latanoprost | 102 | $936 |
| Doxycycline Hyclate | 22 | $593 |
| Timolol Maleate | 11 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $2,695 | $35,57644 claims |
| AbbVieRestasis | $290 | $15,88916 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,491 | $6,18638 claims |
| AlconSimbrinza | $249 | $3,17417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in York
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.